Details of the Drug

General Information of Drug (ID: DMP45ME)

Drug Name
Lisocabtagene maraleucel
Synonyms JCAR017
Indication
Disease Entry ICD 11 Status REF
Large B-cell lymphoma 2A81 Approved [1]
Central nervous system lymphoma 2B33.5 Phase 2 [2]
Follicular lymphoma 2A80 Phase 2 [2], [3]
Non-hodgkin lymphoma 2B33.5 Phase 2 [3], [4], [2]
Richter syndrome 2A81.Y Phase 2 [2]
Precursor B-lymphoblastic neoplasm 2A70 Phase 1/2 [4]
Drug Type
CAR T Cell Therapy
Cross-matching ID
DrugBank ID
DB16582
TTD ID
D0M4WU

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Large B-cell lymphoma
ICD Disease Classification 2A81
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
2 ClinicalTrials.gov (NCT03484702) Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma
3 ClinicalTrials.gov (NCT03310619) A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)
4 ClinicalTrials.gov (NCT03743246) A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
5 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
6 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
10 Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
11 A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
12 ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
13 ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma
14 Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fc receptor IIb inhibitory receptor.Arthritis Rheumatol.2014 May;66(5):1153-64.